Goto Hideki
Department of Hematology, Hokkaido University Hospital.
Division of Laboratory and Transfusion Medicine.
Rinsho Ketsueki. 2023;64(9):1203-1212. doi: 10.11406/rinketsu.64.1203.
Immunotherapies such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy are emerging as new treatments for relapsed and/or refractory hematological malignancies. CAR T-cell therapy has attracted attention as a potentially curative treatment for patients incurable by chemotherapy. However, appropriate management is required to avoid serious complications specific to CAR T-cell therapy, such as cytokine release syndrome (CRS), neurotoxicity (ICANS), hypogammaglobulinemia and prolonged cytopenia, as well as post-treatment infections caused by suppressed immune function.
免疫疗法，如免疫检查点抑制剂、双特异性抗体和嵌合抗原受体（CAR）T细胞疗法，正成为复发和/或难治性血液系统恶性肿瘤的新治疗方法。CAR T细胞疗法作为一种可能治愈化疗无法治愈患者的治疗方法而备受关注。然而，需要进行适当的管理，以避免CAR T细胞疗法特有的严重并发症，如细胞因子释放综合征（CRS）、神经毒性（ICANS）、低丙种球蛋白血症和长期血细胞减少，以及免疫功能抑制引起的治疗后感染。
